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Impaired cellular tolerance of reactive oxygen species (ROS) has been 
suggested as a common mechanistic link associated with aging in both metabolic 
syndrome and nephrolithiasis. The mechanistic (mammalian) target of rapamycin 
(mTOR) activity is characteristic of metabolic syndrome. When nutrients are abundant, 
mTOR is active. Conversely, fasting inhibits mTOR.  Metabolic syndrome is correlated 
with an increased risk of self-reported or imaging findings of nephrolithiasis. At the 
individual level, patients with a higher BMI have an increased prevalence of recurrent 
symptomatic nephrolithiasis, 24-hour urinary excretion of oxalate, sodium, uric acid, 
calcium, and phosphorous as well as lower pH.  Calcium oxalate crystals produce ROS 
in renal epithelial cells and upregulate ROS and also mTOR activity. Rapamycin 
pharmacologically inhibits mTOR leading to autophagy – a natural defense mechanism 
against ROS – and drives sub-cellular recycling machinery to a net catabolic state. 
Ideally, inhibiting mTOR limits the duration and degree of damage done by ROS and 
subsequent inflammatory process. Additionally, improved clearance of damaged 
organelles prevents runaway generation of ROS by mitochondrial dysfunction 
associated with calcium oxalate crystal adherence and internalization. Taken together, 
this may prevent the progression of calcium oxalate urolithiasis. In this study, we 
examined the effect of short-term intermittent rapamycin treatment on the area of 
calcium oxalate concretion in the Malpighian tubules of a Drosophila melanogaster fed a 
lithogenic diet containing 0.1% sodium oxalate. 
Keywords: nephrolithiasis, rapamycin, mTOR, Drosophila melanogaster, calcium 
oxalate, sodium oxalate, Malpighian tubule, aging, metabolic syndrome, reactive oxygen 







  We do not know why obesity and aging are risk factors for kidney stones. With obesity and aging, there is 
opportunity for damage and stress on the body to keep organs like the kidneys from working like they should. As a 
result, we think that this may lead to more risk of forming kidney stones. A pathway called the mTOR pathway might 
help explain why older and more obese people form more stones compared to younger fit people. Our project found 
that using a drug (rapamycin) to slow down this pathway could lower the ability kidney stones to form in a fruit fly animal 
model. The fruit flies given this drug tended to live longer in stressful environments compared to equivalent flies that 
did not get this drug. This finding suggests we should design more experiments to block this pathway either through 
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Excessive caloric intake and low physical activity have been associated with a wide 
variety of age-related diseases associated with reactive oxygen species including 
metabolic syndrome and nephrolithiasis.1 Indeed, elevated body mass index (BMI) is an 
independent risk factor for recurrent symptomatic kidney stone episodes.3  Previous 
studies have correlated higher BMI to abnormal urinary nephrolithiasis parameters and 
recurrent symptomatic stone episodes.2 A major regulator of overall growth in relation to 
nutrient availability is the mechanistic/mammalian target of rapamycin (mTOR) pathway.3 
When active, the mTOR complex coordinates efficiency of cellular processes depending 
on nutrient availability, cell stress and growth factors. Essentially, active mTOR is seen 
as a nutrient “checkpoint”, indicating to the cells that the net environmental conditions are 
favourable to allow for growth and reproduction. Conversely, processes associated with 
lower mTOR activity are involved in breaking down macromolecules. Lower mTOR 
activity leads to increased cellular senescence, apoptosis and protein/organelle turnover 
through increased autophagy. There is mounting evidence that in complex age-




Recently in a dietary rodent model fed ad libitum, calcium oxalate crystal formation 
was associated with  activation of mTOR activity and promoted stone formation.9 
Importantly mTOR activity can be inhibited, either pharmacologically with rapamycin and 
via dietary restriction. Damage of upstream and downstream genes in the mTOR pathway 
may also modulate mTOR responsivity and act in concert with ROS to age related 
conditions like metabolic syndrome and nephrolithiasis.  Drosophila melanogaster (DM) 
is a convenient model organism for studying nephrolithiasis due to homology between 
human nephrons and DM Malpighian tubules. If altering mTOR activity can be shown to 
modulate nephrolithiasis, DM is a uniquely positioned model organism to interrogate how 
the mTOR pathway may help prevent nephrolithiasis. In the following thesis, we will 
determine whether the mTOR inhibitor rapamycin has an effect on calcium oxalate 






The importance of managing nephrolithiasis 
Nephrolithiasis, commonly known as “kidney stone disease”, can be devastating. 
In addition to pain, nephrolithiasis can harbour bacteria and cause bacterial sepsis, 
particularly if there is blockage of urine flow by the stone. With each episode of stone, the 
possibility for acute kidney injury, ureteral stricture, and complications from treatments 
can occur. Chronic kidney disease, defined as a 3 month period of glomerular filtration 
rate (GFR) less than 60 ml/min/1.73m2, elevated markers of kidney damage10, can occur 
from prolonged obstruction by stone, by stricture, or by recurrent kidney infections.  
Observational studies suggest patients with a history of kidney stones are at least twice 
as likely as other patients to develop chronic kidney disease (CKD).11 Prospective cohort 
multivariate analyses have demonstrated that the risk of end-stage renal dysfunction 
(ESRD) requiring renal replacement therapies like dialysis are more than twice as likely 
in female patients reporting a history of stones (OR 2.37, 95%CI 1.13-4.96).11,12 
A significant contributor to the potential morbidity of stone disease it its recurrent 
nature; as any patient with a first episode of stone has around a 50% chance of having a 
recurrent episode within 5 years.13 The indirect morbidity of nephrolithiasis is difficult to 
quantify yet is significant. A vast majority of trials examining quality of life in kidney stone 
patients demonstrate lower quality of life (QoL), bodily pain and general health is worse 
in kidney stone patients compared to control patients.14 Longitudinal follow up with a 
follow up of 18 months, suggests that there is no difference patient reported QoL as time 




to repeat procedures as a result of  recurrent stone episodes, as well as potentially  
unsuccessful procedures, and complications related to both stone disease and prior 
surgical intervention. An estimated 2.1 billion dollars are expended annually in the United 
States for the direct management of urolithiasis, a figure that has increased 50% since 
1994.27 As nephrolithiasis has its peak in 40s-60s, there is certainly a decrease in work 
productivity associated with kidney stones.16 For an average episode of renal colic 
managed in the outpatient setting, patients may miss anywhere from 5 to 48 hours of 
productive working time.17 If the condition of the patient is such to warrant inpatient 
management, the average patient will miss 2-5 days of work.17 Altogether, a review of 
indirect costs from privately insured billings show that the total indirect cost of stone 
disease may be upwards of $775 million US dollars and 3.1 million days off work per 





Epidemiology of nephrolithiasis 
Nephrolithiasis is increasing in prevalence (Figure 1.1).20 In North America, the 
prevalence of urolithiasis from 2007 to 2010 was estimated to be 8.8%  using the Nutrition 
Heath Examination Survey (NHANES) data set.21 Previously, male sex and advanced 
age were described as risk factors for stones, but from a global perspective there appears 
to be an increase in stone prevalence regardless of sex, ethnicity or age.20,22 Kidney 
stone prevalence increased by 16% annually between 1997 and 2012, a pace that 
surpassed the increase in obesity over the same time period.23 The increase 
in stone prevalence can be partially attributable to the increasing use of cross-sectional 
and US imaging. Indeed, the Icelandic group led by Edvardsson found an increase in the 
incidence of urolithiasis from 108 per 100 000 people in 1985 – 1990 to 138 per 100 000 








Figure 1. 1 Prevalence of nephrolithiasis in the United States of America by decade from 
three time periods of NHANES data collection.  
Percent prevalence of stones in USA has increased in all age groups by decade in both 
(A) men and (B) women. The coloured bars indicate different periods of time that 
prevalence data was collected. Figure generated on Microsoft Excel v 16.44 using data 
from NHANES I, NHANES II, and NHANES III collection periods. NHANES = National 







Pathophysiology of nephrolithiasis 
Interestingly, Maloney et al have suggested that urolithiasis tends to cluster around 
regions more so than ethnicity; therefore, metabolic abnormalities and dietary habits may 
outweigh the genetics shared by a particular ethnic group.27 It is also well known that 
nephrolithiasis is more prevalent in hot, arid, dry climates like mountains, deserts or the 
tropics where people are prone to dehydration. The physical chemistry and pathogenesis 
of stones are not fully understood; however, reduced fluid intake is inarguably an 
important mediator of stone formation. At a minimum the supersaturation and nucleation 
of solutes in urine is required.28 Nephrolithiasis formation begins at the level of the 
nephron with the filtration of blood and supersaturation of stone-forming ions in urine. 
Supersaturation occurs when the concentration product exceeds the solubility product of 
solutes in urine. Importantly, stone inhibitors in urine greatly increase the solubility product 
of solutes in urine compared to aqueous solutions lacking these inhibitors. When the 
concentration product exceeds the metastable range of urine with stone inhibitors in 
solution, crystal precipitation may occur. This is known as the formation product. In other 
words, below the solubility product stone crystal formation will not occur, and 
concentrations of solute above the formation product will lead to stones. Increasing the 




Once the formation product level of salt-forming substances is reached, crystals 
require an anchoring site to provide time for crystal growth in order for crystals to reach a 
clinically relevant size. Under normal conditions, the time required for filtered blood to 
become urine and pass though the renal collecting system into the bladder via the ureter 
does not provide sufficient time to allow for significant crystal growth.30 However, 
blockage or “plugging” the collecting ducts of the nephron, local areas of urinary stasis, 
established stone/crystals, damaged cells or even foreign/native materials not normally 
in the urine can contribute to nidus for stone growth by providing an anchoring site.28,30   
  
Non-calcium nephrolithiasis 
Stones are classified according to their composition, and are broadly divided into 
calcium containing stones (oxalate, hydroxyapatite, brushite) and non-calcium containing 
stones (uric acid, struvite, cystine, triamterene, ammonia, silica, drug and matrix stones). 
31 For each of these types of stones, the chemistry of stone formation varies greatly and 
inhibitors for one type may not impact others. Although the metabolic syndrome may be 
associated with both uric acid and calcium oxalate stones, for the purpose of this thesis 





Calcium based nephrolithiasis 
Calcium based stones are responsible for approximately 80% of urolithiasis cases 
in the industrial world.32 Calcium oxalate stones may be either monohydrate or dihydrate 
and may have a minor or major component of phosphate. Primary calcium phosphate 
monohydrate (brushite) stones are more rare than calcium oxalate stones but make up 
approximately 15% of patients with nephrolithiasis.33  Calcium homeostasis is a complex 
process involving the parathyroid glands, kidneys, small intestine, and bone. 34 Calcium 
is absorbed in its ionic state; therefore, impaired calcium absorption can occur when 
complexed with phosphate, citrate, oxalate, sulfate and fatty acids from diet. As a result, 
about 600 – 1200mg of calcium intake will lead to about 100 – 300 mg of absorption, 
primarily by the small bowel. When calcium is low, parathyroid hormone (PTH) through a 
vitamin D-dependent pathway is required to enhance the transcellular absorption of 
calcium at the brush border of intestinal epithelia and maximize calcium resorption from 
kidney. Only about 1-3% of filtered calcium is excreted in the urine due to calcium 
resorption by the kidney; and areas of the kidney most active in calcium homeostasis 
include the proximal tubule (60-65%) and thick ascending limb of loop of Henle (25-30%) 
with the rest being reabsorbed transcellularly in the distal convoluted tubule. 
Hypercalciuria, or elevated calcium in the urine, is the most common metabolic 
abnormality associated with calcium-based stones and may result from any abnormality 





Randall’s plaques and progression of nephrolithiasis 
There are two main theories regarding the growth of kidney stone crystals. Free 
particle stone theory requires the crystallization to occur within the nephron. The former 
theory is supported by the observation that nephron dimensions and physiologic 
parameters of crystal growth are biologically possible.30 Furthermore, there is evidence 
of intermedullary collecting duct “plugs” in certain stone-formers.36–38  Fixed particle 
growth theory assumes that crystal adherence occurs around a stationary “anchor site”, 
providing a favorable environment for growth.39 The stationary site may be exogenous 
(foreign body) or endogenous in the form of different types of crystals (calcium oxalate 
stone developing on a calcium phosphate or matrix nucleus), a previous collecting duct 
“plug”, or on a Randall’s plaque. Randall’s plaques are thought to provide a potential nidus 
for stone formation.  Important work by Evans et al. on renal papillae specimens following 
percutaneous surgery to treat idiopathic calcium oxalate stones revealed that a Randall’s 
plaque may be sub-epithelial and localized to the thin ascending loop of Henle at the level 
of the renal papilla.36 They are composed of matrix and calcium apatite material which 
erode through the urothelium of the renal papilla in order to contact urine and produce 
stones. Indeed, of 5000 calcium oxalate stones analyzed, calcium apatite stone nidus 
was present almost universally in calcium oxalate stone formers.40  
Randall’s plaques are thought to be vascular in origin and vascular injury and 
subsequent repair to the vasa recta or conversion of smooth muscle in nearby blood 
vessels from a contractile to a secretory phenotype may contribute to the process of 





Khan et al. provided a unified theory combining both elements of free and fixed crystal 
theory.42 In this unified theory, an excess of stone forming substrate, or a lack of stone 
inhibitors may lead to free crystals. Upon contact with these free crystals, renal epithelial 
cells may become overwhelmed with maintaining homeostasis  causing an increase in 
oxidative stress which subsequently results in paracrine signalling, inflammation and de-
differentiation of nearby cells. Some cells may then acquire a secretory phenotype and 
deposit calcium phosphate crystals, and this combined with increased sub-epithelial 
metabolism of connective tissue may promote the growth of a plaque. With time and 
further metabolism, the plaque erodes through the epithelium where it can be exposed to 
urine and stone may form.42   
 
Reactive oxygen species, and nephrolithiasis 
 Reactive oxygen species (ROS) are unstable oxygen containing molecules 
that easily react with other macromolecules.43 At high levels, they damage organelles and 
lead to mitochondrial dysfunction contributing significantly to inflammation and cell 
death.44 Autophagy – the process a cell uses to break down its own macromolecule 
polymers – is a mechanism for resistance to cellular stress created by ROS.44 Adhesion 
and internalization of calcium oxalate crystals in the renal tubular epithelium results in 
upregulation of several genes involved in energy metabolism including a major source of 
ROS, NADPH oxidase, at the level of the mitochondria.45 Excessive apoptosis, inefficient 





Inflammation may trigger mineralization of renal interstitial collagen, assisting the growth 
of Randall’s plaques and eventual renal epithelial sloughing.47 Previous authors have 
shown that treatment strategies directed at reducing generation of ROS like 
administration of antioxidant N-acetylcysteine or NADPH oxidase inhibitor apocynin can 
reduce ROS, prevent mitochondrial dysfunction and subsequently reduce nephrolithiasis 





Inhibitors of nephrolithiasis 
The presence of naturally occurring stone inhibitors in solution explains why 
supersaturated urine does not necessarily lead to crystal nucleation, growth, aggregation 
and adherence to renal epithelium.28 Indeed non-stone formers appear to have more 
stone inhibitors in their urine compared to those who form stones.49,50 These inhibitors 
range from ions to large multi-residue amino acids produced at the level of the nephron. 
Small molecules that have shown the ability to raise the solubility of calcium-based stones 
include inorganic citrate, pyrophosphate, and, magnesium.51 In an ex-vivo model of 
supersaturated calcium phosphate solution, the combination of inorganic pyrophosphate, 
citrate and magnesium contributed to approximately 20% of the inhibitory effect of whole 
urine on calcium phosphate crystal formation. The role of citrate in stone prevention relies 
on its presence in urine as a complex with calcium, thereby preventing association of 
calcium with oxalate or phosphate. Citrate also leads to alkalinization of urine and 
exacerbate calcium phosphate stones if urine pH is too alkaline.35 Magnesium may 
chelate with oxalate with a much higher affinity than calcium, reducing the opportunity for 




Macromolecules involved in stone inhibition include glycosaminoglycans, acid 
mucopolysaccharide, RNA, and glycoproteins.28,53 In this class of inhibitors, extensive 
intracellular processing in the rough endoplasmic reticulum and post-translational 
modifications prior to secretion are required for proper physiologic function. Heparin 
sulfate is the most commonly referenced stone-inhibiting glycosaminoglycan, and is 
consistently found in lower concentrations in recurrent calcium oxalate monohydrate 
stone formers compared to non-stone formers.54,5549,50 Conversely, glycosaminoglycans 
appear to be a significant component of apatite matrix in plaques found in Randall’s 
plaques.56 Others have suggested that this observation may be simply non-selective 
presence in matrix due to their relative abundance in urine as albumin and uromodulin 
are also present in high amounts.49 Rather, highly anionic proteins and cationic proteins 
normally found in the intracellular or nuclear compartments represent a disproportionate 
percentage of stone matrix compared to their abundance in urine.49  
There are also several glycoproteins that may act as stone inhibitors; however, the 
two most important are nephrocalcin and Tamm Horsfall protein (THP) or uromodulin.57 
Nephrocalcin is a highly acidic protein with four isoforms produced by renal epithelial cells 
in the proximal tubule and thick ascending loop of Henle.28 Different isoforms of 
nephrocalcin have been shown to have different gamma-carboxygltamic acid residues 
and thus varying affinities for calcium.  This may be clinically relevant as human stone 
formers have been shown to fewer of the strong-inhibitor isoforms and instead produce 
more weak-inhibitor isoforms.58,59 In addition, all isoforms sampled from stone-formers 
had fewer gamma-carboxyglutamic acid residues compared to equivalent isoforms from 




THP is the most common protein found in human urine and is produced by the 
renal epithelia of the thick ascending loop of Henle and distal convoluted tubule. It is a 
membrane-anchored protein that requires cleavage by phospholipase or protease for 
release into urine where it likely has multiple roles including prevention of urinary tract 
infections (UTIs), inhibition of calcium oxalate monohydrate crystal aggregation in alkaline 
urine, and as a regulator of endocytosis of TRPV5 and TRPV6 channels required for 
transcellular Ca2+ resorption in the kidney.28,59,61 Indeed genome-wide association studies 
as well as animal knockout models suggest that THP is a significant inhibitor of calcium 
oxalate nephrolithiasis.41,62,63However, in acidic urine, THP has the potential to change 
conformation and polymerize such that it encourages crystal aggregation, facilitating 





General prevention of nephrolithiasis 
Preventative strategies have in the past focused on addressing dietary , 
anatomical and metabolic risk factors; however, the complete pathophysiology underlying 
these recommendations is not known.28,64 General advice includes increased fluid intake 
to produce >2L urine per day after first stone episode, avoiding dehydration (occupational 
or adverse arid climate exposure), reducing dietary sodium/animal products, and 
identifying underlying medical or anatomic reason for stone formation.35 Unfortunately, 
there is currently no evidence in favor of the primary prevention of nephrolithiasis.65   
Secondary prevention can be achieved through the targeting of identifiable metabolic 
stone parameters, for example increasing citrate intake, moderating oxalate intake, and 
ensuring adequate calcium intake.35 Much of the difficulty in providing new effective 
recommendations, particularly when there is no identifiable risk factor, relates to the 
relative lack of animal models of nephrolithiasis in the context of reactive oxygen species 






mTOR and nephrolithiasis 
The association of  metabolic syndrome with calcium oxalate urolithiasis is an 
active area of current research.64 In particular, ROS associated with metabolic syndrome 
may increase biomineralization on Randall’s plaques and exacerbate oxidative damage 
from hyperoxaluria.41,66 Calcium oxalate crystal adherence  to renal urothelium triggers 
an inflammatory cascade and has been shown to exacerbates stone formation in both in 
vivo and in vitro models.9,67 Furthermore, ROS may upregulate epithelial to mesenchymal 
transition (EMT) of renal epithelial cells to osteoblast-like cells and the ensuing formation 
of Randall’s plaques.47 In addition, further mesenchymal activity results in the excessive 
production of matrix degrading proteins and enzymes thereby allowing the plaques to 
erode through the urothelium and produce a nidus for stone formation. 
Interestingly, mTOR has been described to affect both EMT as well as 
inflammatory responses in various other tissues including cervical68, pulmonary69 and 
renal tissues affected by diabetic nephropathy70. Although there is a paucity of data in the 
literature, there have been suggestions that mTOR is implicated in the pathogenesis of 
obesity-associated renal tubulointerstitial inflammation and urolithiasis.41,71 In one study 
comparing 27 non-obese to 35 obese patients, urinary markers of tubulointerstitial 
inflammation including monocyte chemoattractant protein 1 (MCP-1) and neutrophil 
gelatinase associated lipocalin (NGAL) were elevated in the obese cohort.41 Furthermore, 
examination of kidneys from a high-fat diet rat model of obesity showed evidence of 





Metabolic syndrome, aging, and, nephrolithiasis 
Interestingly, stone disease is increasing in parallel with the increasing prevalence 
of metabolic syndrome, which affects 1 in 4 Americans and is rising in pediatric 
populations. 1,72 Metabolic syndrome has multiple definitions. However, it is universally 
defined by the presence of insulin resistance, obesity, hypertension, and dyslipidemia 
and leads to an increased risk of cardiovascular disease and accelerated 
atherosclerosis.1,72,73 A meta-analysis of large retrospective datasets suggests that 
metabolic syndrome is correlated with increased risk of self-reported or imaging findings 
of urinary stone disease.73 At the individual level, patients with a higher BMI have 
increased prevalence of recurrent symptomatic urolithiasis, 24-hour urinary excretion of 
oxalate, sodium, uric acid, calcium, and phosphorous as well as lower urine pH.74,75 
Hyperinsulinemia, an eventual end result of the metabolic syndrome, has been 
associated with hypercalciuria in obese patients who form stones.76,77 The risk of calcium 
and uric acid based stones is higher for obese individuals.2,78 Furthermore, even with 
accounting for confounding risk factors, nephrolithiasis has been associated with the 





There exists differences in the rates of urinary stone disease amongst different 
racial groups.  Despite all ethnicities suffering the burden of urolithiasis, the highest 
prevalence of nephrolithiasis is in Caucasians and is positively correlated with income 
and a sedentary lifestyle.25  For example, Soucie et al has shown that the highest 
prevalence of stone disease in Caucasians followed by Hispanic, Asian, and, African 
Americans.79 Examination of emergency department demonstrate differences in the 
gender predominance of stone disease in different ethnicities. For example, Dall’era et al 
showed a male to female ratio of 2.05 for Caucasians compared to 1.17 for Hispanics. 
Furthermore, Sarmina et al in 1987 described an incidence in symptomatic nephrolithiasis 
with a male: female ratio of 2.03 in Caucasians vs a 0.63 ratio in African Americans.80 
This finding of increased male predominance appears to hold true today, however the 
authors of a study in South Carolina in 2019 have suggested that the greatest increase 
in stone disease were observed in adolescents, females and African American patients.23 
Strikingly, the prevalence of stone disease doubled in children and there was a 45% 





Age has an interesting relationship with both nephrolithiasis and metabolic 
syndrome. According to Stats Canada, the percentage of adults who are obese increases 
with increasing age.81 Between the ages of 40 and 60, over 70% of men and 60% of 
women are obese or overweight in Canada.81 In contrast, 8.5% of children aged 5 to 9 
years old  are obese; however the prevalence appears to be rising.82 Historically, the 
incidence of nephrolithiasis peaks beginning at age 40 and is more common until age 60; 
however, in parallel to the increasing rates of obesity, it is becoming more common for 
kidney stones to affect people under the age of 20.28.83,84 Interrogation into a national 
pediatric database including all admissions, emergency and outpatient visits from 1999 – 
2008 related to nephrolithiasis revealed an increase in paediatric patients treated for 
stones from 18.4 per 100 000 in 1999 to 57 per 100 000 in 2008.85 Although consistent 
evidence exists for a trend in the annual increase in pediatric nephrolithiasis, the 
pathophysiology behind this observation has been elusive. Ultimately, obesity and 
metabolic syndrome have been suggested as comorbid conditions that may have a role 






mTOR pathway and metabolic syndrome  
Recently, the mTOR pathway has been suggested as a key pathway at the 
crossroads of urolithiasis and metabolic syndrome. mTOR is a highly conserved 
serine/threonine protein kinase recognized as a central coordinator of growth and 
metabolism which is found from yeasts to higher order organisms including insects and 







Figure 1. 2 An overview of the mTOR pathway as a mediator of the correlation between 
metabolic syndrome and nephrolithiasis.  
The positive influence of various pro-growth signals including growth factors, abundant 
micronutrients and environmental stimuli lead to an increase in mTOR activity. The 
aggregate effects of mTOR activity are pro-anabolic at the cellular level. In general, tissue 
growth leads to the metabolic syndrome phenotype. In parallel, the effects of mTOR 
specifically at the local level of the kidney or gastrointestinal (GI) tract may promote 
nephrolithiasis by several mechanisms correlated with increased mTOR activity. For 
example, an increase in protein synthesis and post-translational processing may lead to 
an increase in defects in the processing of macromolecules.Defective macromolecules 
may still function reasonably well in most cases, but stone inhibitor proteins that are 
associated with nephrolithiasis might not provide the same protection against kidney 
stones. The impact of reduced mTOR activity on tissue repair and turnover may 




epithelial barrier function of GI tract and kidney urothelium may also be affected by mTOR 




When mTOR is activated, its core protein (Figure 1.3A) joins other proteins to form 
one of two complexes: mTORC1 or mTORC2 (Figure 1.3B and 1.3C). The appropriate 
subcellular location and specification of mTORC1 is defined by the binding of mTOR to 
the regulatory protein associated with mTOR (Raptor).3 Raptor is a scaffolding protein 
that facilitates and stabilizes protein-protein interactions for mTOR substrate proteins to 
the TOR signaling motif (TOS). In addition, mTOR associated protein, LST8 homolog 
(mLST8) and Deptor proteins are also required for mTORC1 activity, as it helps stabilize 
the active catalytic site of mTOR protein kinase domain (Figure 1.3B).3,87,88  
Tuberous sclerosis complex (TSC) protein is an upstream regulator of mTORC1 
(Figure 1.4A). 3 When TSC is active, it inhibits mTORC1. Canonical signaling cascades 
impacting mTORC1 activity include IGF-1/AKT/PTEN, MAPK-Erk, Wnt and TNF-alpha 
pathways.87 In particular, ATP deprivation during starvation activates AMPK. The active 
AMPK protein then inhibits mTORC1 via Raptor phosphorylation. Ultimately, ATP 
deprivation leads to activation of TSC2 through the signalling cascade above.88,89 
CASTOR is another component of mTORC1 that allows for detection of lysosomal 
amino acid concentrations.90 When amino acids are present in adequate amounts, 
RagGTPases bind to CASTOR. When CASTOR is bound by RagGTPase, there is a 
conformational change that occurs increases Raptor’s affinity its mTOR binding site, 
stabilizing the mTORC1 complex. Therefore, effective mTORC1 signaling is only possible 




mTORC1 activity couples growth signals with nutrients available in the 
extracellular milleu in order to promote anabolic cellular activities (Figure 1.4B). S6 Kinase 
(S6K) is downstream of mTORC1 activity and is the protein responsible for the initiation 
of mRNA translation/processing.61 Transcription factors required for de novo lipid 
synthesis are regulated by mTORC1 through the sterol responsive element binding 
protein (SREBP), which is activated through the activation of S6K and the inhibition of 
Lipin 1.86  In addition, de novo purine and pyrimidine synthesis is upregulated through 
mTORC1 activity.3,4 Finally, through hypoxia inducing factor alpha (HIF1a) and c-Myc 
mTORC1 activity leads to increased glycolysis.  Through this process, NADPH and other 
intermediates of the citric acid cycle are produced which use abundant environmental 
energy and macromolecules and promote organism growth.91  
Importantly, mTORC1 activity is associated with reduced autophagy. When 
nutrients are abundant, mTORC1 acts via AMPK to phosphorylate and inhibit ULK1, 
which subsequently serves to inhibit autophagy. In addition to impairment of apoptosis 
under inappropriate conditions, lysosomal biogenesis and creation of proteins required 
for autophagy machinery is inhibited by mTOR through protein TFEB. Therefore, active 
mTORC1 appropriately limits macromolecule recycling through autophagy in settings 





In contrast, mTORC2 is responsible for cellular proliferation, cell-cell interactions 
and cytoskeletal rearrangement (Figure 1.4B and 1.5B). mTORC2 is defined by mTOR 
binding to rapamycin insensitive companion of mTOR (RIctor) in addition to mLST8.  The 
rapamycin-FKBP12 complex does not bind to mTOR when it is bound to Rictor as 
mTORC2, however chronic use of rapamycin may limit the number of mTOR molecules 
and lead to insulin resistance as it can inhibit the downstream AKT/PKB pathway.92 
Downstream actions of mTORC2 includes cytoskeletal remodeling and insulin signalling.  
In addition, mTORC2 is also involved in cell survival, endocytosis/exocytosis, and ion 
transportation through the regulation of serine/theonine-protein kinase-1 (SGK1) (Figure 
1.5B).3   
In summary, the physiologic role of mTOR is conserved in a wide range of species. 
These are accomplished through two protein complexes: mTORC1 and mTORC2 that 
have different downstream pathways. Common intracellular processes involving mTOR 
include glucose homeostasis, adipogenesis, lean mass homeostasis, immune function, 
autophagy associated with aging and cellular proliferation.3,86 Since the mTOR pathway 
controls the cell recognizing cues to grow in its environment, manipulation of this pathway 
may influence the development of metabolic syndrome and likely other physiologic 





Figure 1. 3 (A) The core mTOR protein has several domains required for proper function 
and regulation.  
The mTOR core protein executes its function via its kinase domain near the c-terminus 
of the protein. HEAT = Huntingtin, Elongation Factor 3, Protein Phosphatase 2A, mTOR 
(acronym of four proteins in which this repeat structure is found), FAT = Focal Adhesion 
kinase Targeting, FRB = FKBP12-Rapamycin Binding, FATC= Focal Adhesion kinase 
Targeting C-terminal. (B) The mTORC1 complex is defined by the interaction of the 
mTOR core protein with a scaffold protein called Raptor. Rapamycin inhibits mTORC1 
complex activity by complexing with FKBP12 and binding the mTOR core protein FRB 
domain. The regulation of mTORC1 is complex and can occur through interactions at 
other domains. For example, the PRAS40 protein inhibits Raptor’s ability to complex with 
the mTOR core protein. Other proteins known to inhibit mTORC1 complex activity 
independent of Rapamycin-FKBP12 include Deptor and mLST8. Raptor = Regulatory 
associated protein of mTOR. PRAS40 = proline rich Akt (acutely transforming retrovirus 







Binding Protein 12. (C) The mTORC2 complex is defined by interactions with the Rictor 
protein.  
In order for Rictor to complex with the mTOR core protein, Protor1/2 and mSin1 must be 
present. Note: Rapamycin-FKBP12 does not directly inhibit mTORC2. Other proteins 
known to inhibit both the mTORC1 and mTORC2 complexes, independent of Rapamycin-
FKBP12. These include Deptor and mLST8. Raptor = Regulatory associated protein of 
mTOR.  Rictor = Rapamycin insensitive companion of mTOR, Protor1/2 = Protein 
observed with Rictor 1 and 2, mSin1 = mammalian stress-activated protein kinase 
interacting protein 1, Deptor = DEP (Dishevelled, Egl-10, Plekstrin) domain containing 
mTOR-interacting protein. mLST8 = mammalian Lethal with SEC13 protein 8.3 
 














Figure 1. 4 Negative regulators of mTORC1 and mTORC2.  
In the absence of amino acids and growth factor activity, mTORC1 is sequestered by 
CASTOR1 protein in the cytoplasm of the cell. Furthermore, scaffold protein Rictor is not 
activated by Rheb and lysosomal scaffold composed of Rag proteins are not assembled. 
Inactivity of mTORC2 is maintained by conversion of PIP3 to PIP2 by PTEN and Ras 
sequestering by NF1. (B) Major positive regulators of mTORC1 and mTORC2. Amino 
acids, particularly arginine and leucine are necessary but not sufficient for mTOR activity 
by preventing CASTOR protein sequestering of mTORC1.  Insulin, FGF and EGF are key 
growth factors that promote mTOR activity via their G-coupled protein receptors and 
downstream intracellular signalling pathways involving phosphoinositol metabolism and 
Ras cascade. The active mTORC2 affects Akt and vice versa, potentiating the 
downstream effects of both insulin-response and mTORC2 signalling pathways. Finally, 
the insulin and fibroblast/epidermal growth factor pathways, as well as the products of 
inflammatory signalling via NF-κB, lead to inhibition of the TSC1/2 complex and permit 
mTORC1 localization at level of the lysosome whereby it is required to function. CASTOR 
= Cytosolic arginine sensor for mechanistic target of rapamycin complex 1, Rag = 
Recombination activating gene, Ragulator = Regulator of Rag, v-ATPase = v-Type 
adenosinetriphosphatase, SLC38A9 = Solute carrier family 38 member 9, Rheb = Ras 
homolog enriched in brain, IRS = insulin response substrate, PI3K = Phosphoinositol-3-
kinase, PIP = Phosphatidylinositol, PIP-2 = Phosphatidylinositol 4,5-bisphosphate, PIP-3 
= Phosphatidylinositol 2,4,5-trisphosphate, AKT = Ak strain transforming, PKD1 = 
Polycistin 1, Ras = Rat sarcoma protein, Raf = Rapidly accelerated fibrosarcoma protein, 
MEK = Mitogen-activated protein kinase/extracellular signal-regulated kinase, ERK = 
Extracellular regulated kinase, TSC1/2 = Tuberous sclerosis complex 1 and 2, TNF-α = 
Tumour necrosis alpha,  IKK α = IκB kinase alpha, GSK3B = Glycogen synthase kinase 
3B, LKB1 = Liver kinase B1, AMPK = AMP-activated protein kinase, PTEN = 















Figure 1. 5 The downstream effects of mTORC1 and mTORC2 signalling normally 
complement one another.  
(A) The mTORC1 complex is responsible for the increase in basic anabolic properties of 
mTOR activity like increased glucose utilization, mRNA translation, positive net protein 
balance and cellular supply of nucleotides, sterols. S6K = Serine-6-Kinase Protein, 4EBP 
= 4E-Binding Protein, ATF1 = Activating Transcription Factor 1, TFEB = Transcription 
factor EB, SREBP = Sterol Regulatory Element Binding Proteins/, HIF1α = Hypoxia 
Inducible Factor 1-alpha, PGC1 α = Peroxisome proliferator activated receptor Gamma 
Coactivator 1-alpha, ATF4= Activating Transcription Factor 4.  (B) The mTORC2 complex 
is chiefly involved in survival processes of the cell undergoing stress including cell motility 
and ion/fluid regulation. SGK = Serine/Threonine-protein Kinase, Foxo1/3a = forkhead 
box class-O protein 1 and 3a, PKC = Protein Kinase C, AKT = Ak strain Transforming 
protein.3 
Autophagy and mTOR  
 Autophagy is a catabolic process that lies at the interface of reactive oxygen 
species and cell stress response.93  The goal of autophagy is to degrade damaged 
organelles or proteins in order to release stored energy or re-purpose nutrients that the 
cell requires.94 The first step in autophagy involves ROS or reactive nitrogen species 
(RNS) triggering signalling cascades.95 Subsequently, rearrangement of cytoplasm 
compartmentalizes the substance of interest to be degraded into autophagosomes.94 
Autophagosomes then fuse with lysosomes where hydrolase enzymes catalyze 
degradation.96  
mTOR dependent phosphorylation of ATG13 suppresses ULK1 and prevents 




and biogenesis through phosphorylation of TFEB that keeps it in a cytosolic location when 
active.90  
Autophagy can also be regulated by ROS and other pathways in a non-mTOR dependent 
manners, adding to the complexity of this process.97 Age-related diseases like metabolic 
syndrome and cardiovascular disease exhibit reduced efficiency of autophagy.98 
Inefficient autophagy results in impaired tolerance of ROS and subsequent cell death or 
further damage99  
 
Rapamycin and inhibition of mTOR 
Rapamycin is a molecule isolated from Streptomyces hygroscopius found in the 
soil of Easter Island (Rapa Nui).100 Rapamycin requires a protein called FKBP12 in order 
to inhibit mTOR.101 The rapamycin-FKBP complex is an allosteric partial inhibitor of 
mTORC1 kinase and binds directly to mTOR at its FRB domain3. Therefore, when mTOR 
is inhibited by rapamycin, catabolic processes such as autophagy are upregulated and 
drive sub-cellular recycling machinery. In addition, PI3 kinase signaling required for 
insulin signaling is inhibited by rapamycin.102,103 The benefits of mTORC1 inhibition may 
be limited to acute dosing of rapamycin; however, as chronic exposure to rapamycin may 
exacerbate diabetogenic phenotypes.104 With less mTOR protein available to form 
mTORC2, cells cannot orchestrate subsequent processes required for appropriate 





Clinical Uses of Rapamycin and Side-Effects 
 Rapamycin is indicated in the treatment of lymphangioleiomyomatosis,106 as part 
of immunosuppression regime for renal transplant107 and a component of drug eluting 
stents for percutaneous coronary artery revascularization after myocardial infarction.108 
Rapamycin has also been used off-label to treat autosomal dominant polycystic kidney 
disease (ADPKD),109 renal angiomyolipomas,110 and other solid-organ transplants (heart, 
lung, and liver).111 Renal transplant immunosuppression regimes may include rapamycin 
mycophenolate mofetil but usually include prednisone induction, a calcineurin inhibitor 
(cyclosporin or tacrolimus) or mycophenolate mofetil.112 To our knowledge, rapamycin (or 
immunosuppression in general) has never been suggested as part of a preventative 




Importantly, rapamycin has well described serious complications from chronic use: 
type 2 diabetes mellitus, hypertriglyceridemia, bone marrow toxicity (anemia 12-76%, 
leukopenia 11%, thrombocytopenia 30%), gastrointestinal irritation (15-20%), oral ulcers 
(10-19%), thromboembolic diseases (17%), interstitial lung disease (4-17%),  
angioedema/lymphedema (2.2-15%), proteinuria (10%), glomerulonephritis (2%).111 The 
therapeutic range of rapamycin to avoid toxicity while preventing renal transplant rejection 
is between 4-20 µg/L.113 Oral bioavailability of sirolimus is approximately 15% with a large 
volume of distribution in humans including in red blood cells and fatty tissues (5.6-16.7 
L/kg).114 The half-life of rapamycin is dependent on metabolism by cytochrome P-450 3A4 
(CYP3A4).114 Rapamycin is rapidly absorbed, metabolized with time to peak dose of 1 
hour, and has a half-life between 39.3 – 86.5 hours.115 CYP3A4 has many substrates 
including estradiol and may explain some of the variation in drug clearance between men 
and women.114,115  
Specifically, rapamycin has been associated with obesity and metabolic syndrome 
in the kidney transplant population.116 Several studies have shown an increased risk of 
developing new-onset type 2 diabetes mellitus (NOTDM) after conversion from a 
calcineurin inhibitor to rapamycin (sirolimus) as part of immunosuppression rejection 
prophylaxis.117–119 Additionally, NOTDM has been associated with an increased 
cardiovascular mortality and hypertriglyceridemia after kidney transplant.120 Despite a 
high prevalence of obesity and metabolic syndrome in the kidney transplant population, 
the incidence of kidney stones is reported between 1-1.7% it is generally a rare 





Clinical correlate of overactive mTOR: Autosomal dominant polycystic kidney 
disease and risk of nephrolithiasis 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common 
hereditary kidney disease with a prevalence of 1 in 1000 to 1 in 2500 individuals.123 It is 
characterized by multiple cysts affecting both kidneys. Individuals with ADPKD typically 
develop urolithiasis earlier than the general population, at a median age of 37.83,123 The 
formation of urolithiasis in ADPKD patients has been associated with higher rates of 
hyperoxaluria and decreased ammonia excretion.85 Mao and colleagues have shown that 
the formation of urolithiasis in ADPKD patients is associated with higher rates of 
hypocitraturia, hypomagnesuria, low urine pH, impaired uric acid metabolism, and 
hypophosphatemia compared to stone formers without ADPKD.124 Additionally, ADPKD 
patients have been shown to have an increased incidence of post-transplant diabetes 
mellitus, lipid abnormalities and cardiovascular disease risk compared to all renal 
transplant recipients.124  
A multitude of genes are associated with this condition, however the most classical 
genes are PKD1 and PKD2 and are typically inherited in an autosomal dominant 
manner.125 However, ADPKD has also been described to occur without a positive family 
history; implying a possible de-novo mutation, germline/somatic mosaicism or epigenetic 




Loss of these proteins lead to reduced intracellular calcium and reduced PDE1 
activity, resulting in excessive cAMP production and cystogenesis through activation of 
proliferation and secretion pathways.127 In the absence of PKD1, there is aberrantly active 
mTOR, and in fact high levels of mTOR activity have been observed in models of 
ADPKD.88This may result through the interactions of PC1 and TSC2 which typically inhibit 
mTORC1 formation and is known to be inactivated in certain models of ADPKD.88 
Historically, the development of nephrolithiasis in ADPKD has been thought to be 
related to CKD and mechanical obstruction from the size of cysts.128 Recommendations 
for these individuals includes maintaining a healthy lifestyle and diet, avoiding smoking 
and  non-steroidal anti-inflammatory medications (NSAIDs).129 Vasopressin receptor 
inhibition, either through drinking water or tolvaptan, leads to decreased cAMP and may 
prevent downstream activation of mTOR and other pro-growth pathways; thereby 
decreasing cystogenesis.129 Initial murine models investigating mTOR inhibition were 
promising in preventing the progression of PCKD; however, phase 3 clinical trials 
assessing everolimus and rapamycin failed to demonstrate decreased disease 







Calcium oxalate crystals activate mTOR and exacerbate nephrolithiasis 
Unno et al recently suggested that autophagy is crucial in ensuring an appropriate 
homeostatic response to calcium oxalate monohydrate exposure and that this can be 
perturbed by an abundance of calcium oxalate monohydrate in the environment. In 
addition, less calcium oxalate monohydrate was required in the presence of an autophagy 
inhibitor 3-methyladenine. Finally, a more select mTORC1 inhibitor called Torin1 was 
shown to increase autophagy and may protect cells from the effect of downregulated 
autophagy caused by calcium oxalate monohydrate exposure. With more efficient 
autophagy, less inflammation and crystal aggregation was observed.  
Importantly, when mice were treated with rapamycin after 4 days of oxalate 
administration, they had less calcium oxalate crystal deposition in their kidneys. The 
authors concluded that increased mTOR activity is a major cause of compromised 
autophagy by oxalate administration and that this can be remedied by mTOR inhibition in 
vivo. 9 The presence of phosphorylated SQSTM1, which serves as a marker of impaired 
autophagy, has been shown to be present in the renal mucosa of stone-forming kidney 











Drosophila melanogaster as a model of nephrolithiasis  
DM has been used as a model organism to study the effects of rapamycin and 
mTOR as well as obesity, heart disease, insulin signaling and ROS generation in 
metabolic syndrome-like states.130–132 When DM is subjected to excess exogenous fat, 
cardiac cells and liver cells accumulate fat in addition to elevated hemolymph triglycerides 
which is analogous to humans.130 In addition, insulin leads to activation of GLUT4 insulin-
dependent glucose transporter and a feed-forward insulin release in both DM and 
mammals; therefore, DM also a physiologically relevant model for diseases of insulin-
resistance despite initial concerns regarding different sugar metabolism than in 
humans.107 Indeed, the mTOR pathway has shown to be overactive in a high-fat diet 
induced obesity model using DM.130 In this model, inhibition of mTOR via rapamycin has 
been shown to protect the heart and internal organs in DM from elevated hemolymph 
triglycerides.130 
The DM model of renal stone disease is a well validated model to study urolithiasis 
due to its remarkable homology to humans (Figures 1.6, 1.7, and, 1.8).133,134 The basic 
role of the urinary system is to filter, reabsorb and secrete solutes from the blood to and 
from the urine. Once created, the urine is to be eliminated. In humans, the formation of 
urine is accomplished by the nephron: which is comprised of the glomerulus, proximal 
tubule, loop of Henle, distal tubule and collecting duct which does all of the filtering, 
resorption and secretion (Figure 1.6A).34 The human glomerular vasculature is lined by 
podocytes. Fluid then passes through the podocyte filter based on net interstitial pressure, 






Figure 1.6 Functional homology and structural differences between mammalian 
nephrons and arthropod Malpighian tubules  
(A) Mammalian nephron and (C) arthropod Malpighian tubule. (B) Podocytes and (D) 
Nephrocytes importantly share fenestration properties that permit them to act as a semi-
permeable selective filtration barrier. (Weavers, Helen et al. “The Insect Nephrocyte Is a 
Podocyte-like Cell with a Filtration Slit Diaphragm.” Nature 457.7227 (2009): 3220326. 





Renal epithelial cells that make up the nephron then act to modify the 
concentrations of substrates in the ultrafiltrate produced by the glomerulus.34 Urine is then 
sent via the renal papilla into the minor calyces, major calyces, renal pelvis, ureter and 
finally to the bladder to be eliminated when convenient per urethra. In contrast to humans, 
DM circulatory system is avascular. Instead, DM have a complex fluid called “hemolymph” 
that moves nutrients, wastes and hormones between structures in the fly.133 DM have an 
analogous structures comparable to the glomerulus that filter hemolymph, called 
nephrocytes (Figure1.6 C).133 The nephrocytes are located in the pericardium and have 
a similar diaphragm, with small foot processes spaced 30nm apart with an underlying 
basement membrane. Akin to the human podocytes, the nephrocyte foot processes form 
a barrier to particle size and charge, resulting in filtration of the hemolymph (Figure 1.6 
D).135 The filtered hemolymph then enters the Malpighian tubules, which is homologous 
to the human tubular system of the nephron.135 There are four Malpighian tubules in a 
DM, each comprised of three segments called the initial, transitional and main 
segments.133,136 These segments are composed of either principal or stellate cells which 
manage the ion concentration of the luminal aspect of Malpighian tubules. Finally, each 
pair of Malpighian tubules join together to form a short “ureter” that connects the tubule 





Figure 1.7 Malpighian tubule (MT) segments.  
(A) Principal cells dominate the initial and earl transitional segment of the MT whereas 
the stellate cells are primarily found in the distal half of the transition and throughout the 
main MT segments. (B) Principal and stellate cells with their respective ion and solute 
transport mechanisms. Osmosis occurs transcellularly. (Denholm, Barry et al. “The 
tiptop/teashirt genes regulate cell differentiation and renal physiology in Drosophila.” 
Development (Cambridge, England) 140.5 (2013):1100-1110. PMC). MG = Midgut, HG = 
Hindgut. V-ATPase = V-type adenosine-triphosphatase, cGMP = cyclic guanosine 
monophosphate, cAMP = cyclic adenosine monophosphate, capa 1/2 = Capability 
peptides 1 and 2, DH31/DH44 = Diuretic hormone 31 and 44, LK = Leucokinin, LKR = 





DM have been used as a model for calcium oxalate nephrolithiasis since 2011.137 
Although urolithiasis in this model is not spontaneous, it is relatively easy to form stones 
via supplementation of lithogenic agents like ethylene glycol or sodium oxalate.133,138 
Tubular concretions of calcium oxalate crystals are analogous to urinary stones and have 
been confirmed by scanning electron microscopy and energy-dispersive x-ray 
spectroscopy.138 Furthermore, due to the evolutionary conservation of ion channels and 
cellular pathways between the Malpighian tubules and human nephrons, administration 
of drugs known to impact certain types of stone formation like hydroxycitric acid have 
worked in this model.139 Further advantages of this model include its high throughput 
ability; consequently, DM can be an extremely economical in vivo model with low-
maintenance husbandry requiring relatively rudimentary equipment.114 In terms of the 
study of stone burden, DM tubules are transparent, thus simple light microscopy allows 








Figure 1. 7 DM Malpighian Tubule anatomy.  
A) Light micrograph of dissected (B) Artistic rendition of relevant DM anatomy for study 
of nephrolithiasis. Each pair of Malpighian tubules are connected to the hindgut via a very 








Calcium oxalate crystals can activate mTOR and exacerbate the effect of ROS on 
the formation and progression of calcium oxalate kidney stone disease.9 Therefore, we 
hypothesize that calcium oxalate concretion formation in the Malpighian tubules of DM 
treated with intermittent doses of rapamycin (an mTOR inhibitor) will be significantly less 
than individuals not treated with rapamycin. We also hypothesize that treatment groups 
fed a lithogenic diet while intermittently fasting every 24 hours on agar will have less 
calcium oxalate concretions in their Malpighian tubules compared to a lithogenic 
alternating with NF (ad libitum) diet early in the life of the fly.  Additionally, mTOR inhibition 
has also been associated with an increase in life expectancy in animal models.3 We 
hypothesize that life expectancy of DM treated with rapamycin will be significantly longer 
compared to control groups with and without lithogenic diets. Finally, we expect that 
treatment groups fed a lithogenic diet while intermittently fasting every 24 hours on agar 






Materials and Methods 
Ethics 
DM are an invertebrate organism and as such experiments are exempt from 
requiring animal ethics board approval. All insects were handled according to the 
Canadian Council on Animal Care (CCAC) Guidelines140 
 
DM Husbandry 
CantonS (Stock #64349) wild type strain Drosophila flies were obtained from 
Bloomington Stock Center, Indiana, USA (http://fly.bio.indiana.edu). All stocks were 
maintained in plastic 50mL Erlenmeyer wide fly vials (Genesee Scientific Corporation, 
CA). Stocks were stored separate from sample flies to avoid mite infestation. Twenty-five 
to fifty DM individuals were mated for 18-24 hours on standard media with yeast paste 
and grape agar. Flies that were no longer required were disposed of, in an Erlenmeyer 
flask containing 70% ethanol. Eclosed (recently having emerged from the pupal state) 
DM were allowed to mature 24 hours prior to first dose of anaesthesia, or treatment.  Wide 
fly vials (GEN32-121, Genesee Scientific, California, USA) were used for housing 
samples during experimentation. At all times except for changing flies from vial to vial, 
stocks were maintained in a DM incubator (DigiThermâ Drosophila Incubator, Tritech 
Research Inc.) at a humidity of 40%, a temperature of 25°C, and were exposed to a 12-




DM were transferred under gentle carbon dioxide (CO2) anaesthesia (Flystuff 
Flowbuddy Flow Regulator with Ultimate Flypad, 590122BCU) for 5 seconds, for a total 
of 10 seconds of hypoxia, from food medium to treatment agar in fly vials every 24 hours. 
DM were observed for 10 minutes after anaesthesia transfer and any dead or escaped 
individuals were censored from life-expectancy data. Food media and agar tubes were 
changed every 5 days.   
 
Production of DM food media 
Individual batches of food media were produced in one-litre volumes. Ingredients 
were weighed using a digital scale (Sartorius AG, Goettingen, Germany) and heated 
using a hotplate in a non-sticking commercially available cooking pot. Freshly prepared 
media was pipetted into the wide polypropylene vials using a disposable pipette. A grade 
50 cheesecloth was placed to reduce the risk of contamination while cooling prior to 
placement for storage. Vials were covered by cellulose acetate plugs (Flugs GEN49-101, 
Diamed Inc., Ontario, Canada) and left to cool overnight to reduce condensation prior to 





Standard food DM media and agar 
Standard food as defined in this study was prepared according to a previously 
utilized formula (Bloomington #1) which provided DM with adequate nutrients for 
development in lab environment.141,142 (Table 2.1).  One-thousand mL of distilled water 
was brought to a rolling boil. Agar was added and stirred until clear. For agar tubes, this 
mixture was allowed to cool and then poured into wide vials in 10mL aliquots. For all other 
media, cornmeal was then stirred in until a thick formula formed. Yeast was then added 
and stirred until dissolved. Corn syrup was then added prior to cooling. The mixture was 
allowed to cool prior to adding propionic acid to media as a preservative. Finally, the 
mixture was decanted in 10mL aliquots into wide vials as described previously. 
 
Table 2.1 Ingredients used in the preparation of standard Drosophila lab media  
(“Normal Food”).  





Lithogenic DM media 
Lithogenic food as defined in this study is 0.1% (weight/volume) sodium oxalate 
(NaOx) dissolved in the standard DM food prior to cooling to room temperature. For each 
replicate, normal media was separated by 50% volume. Five-hundred mL was poured 
into a 1L beaker and 0.5mg of sodium oxalate was added to the mixture and stirred 
thoroughly until fully dissolved. The ensuing lithogenic mixture was then decanted in 





Microcapillary rapamycin dosing 
The CAFE method of drug delivery in DM has been previously described (Figure 
2.1).143 Briefly, 5% agar is poured into the base of fly tubes. The cotton lids are pierced 
by a 100 μL pipette and the same pipet is used to hold a fine capillary inside the vial 
through the pipette tip. Using capillary action, approximately 5-10 μL aliquots of 
rapamycin solution were loaded into the capillary. The fly tubes are then closed and the 
capillary containing rapamycin and vehicle, or vehicle alone are placed in the pipette. 
Flies in the experimental group were fed normal food media with dissolved 0.1% 
(weight/volume) sodium oxalate (lithogenic media). The experimental group alternated 
daily between a vial containing lithogenic media and a vial of non-nutritious 5% agar with 
100 uM rapamycin dissolved in 10 μL of 100% ethanol and 5% sucrose (weight/volume) 
accessible by a microcapillary. Our control groups were fed normal media alternating 
every 24-hours on an agar tube. Each agar tube contained a capillary filled with 10 μL 
ethanol and 5% sucrose (weight/volume) solution +/- 100 μM rapamycin (Figure 2.2). Our 
positive control group alternated between standard and lithogenic media every 24h 
without use of CAFE (Figure 2.2). All DM were placed on 5% agar (weight/volume) to 














Figure 2.1 Diagram of the Capillary Feeder (CAFE) assay.  
In this method of feeding, DM climb up the sides of the vial filled with agar and take up 
substances within the capillary housed within the pipette tip. EtOH = 100% ethanol, w/v 






Experimental and control diet groups were studied with both males and females 
separated. Twenty flies per replicate were included in the positive control groups (Figure 
2.2A). All experiments were performed over a duration of 10 days. Drosophila in in this 
group were fed lithogenic food on day 1, anesthetized at the beginning of day 2 and 
transferred to normal food for 24 hours. This was repeated for a total of 10 days.  
Flies were fed lithogenic food on day 1, and then transferred to tubes containing 
agar and a capillary with vehicle (ethanol + 5% sucrose) on a 5% agar base on day 2.  
These media tubes were then alternated every 24 hours for 11 days post eclosure (Figure 
2.2B). The negative control group was fed normal food on day 1, and then maintained on 
a capillary containing ethanol with 5% sucrose on a 5% agar base for the remainder of 
the experiment. The first experimental group alternated between normal food every 24 
hours with 100µM rapamycin on 5% agar. The second experimental group alternated 
between lithogenic food and 100µM rapamycin on 5% agar (Figure 2.2A). Five replicates 
of each control and treatment group were performed to achieve an adequate number of 
Malpighian tubules for analysis. No formal power calculation was calculated; however, 










Figure 2. 2Diagram of control and treatment groups.  
(A) Daily alternating lithogenic (0.1% NaOx), or normal food with agar or normal food 
identified by arrows. (B) Flowchart for experiments. The fly tubes were changed every 24 
hours as marked by the X. On the 11th day post eclosure, each group was dissected for 
Malpighian tubule analysis, whereas life expectancy vials were to continue until endpoint 







= sodium oxalate, q24h = every 24 hours. Optimal dosing of rapamycin was not 
determined in this study. 
Malpighian tubule isolation 
CO2 was used to euthanize DM at the completion of the experiment at 10 days. 
DM were then transferred to a 1 mL Eppendorf tube containing 99% ethanol for 3 minutes, 
and then to a Petri dish (Pyrex 3160100, Sigma-Aldrich Inc) lined with Sylgard (Dow 
Corning Inc., MI, USA) that contained 10mL of phosphate-buffered saline (PBS) via fine 
tipped forceps. DM dissections (Figure 2.4) were completed within 45 minutes of 
immersion in PBS and placed in a solution of 37% formaldehyde diluted 9:1 with PBS for 





Figure 2.3 Malpighian tubule dissection via hindgut traction (HG). Malpighian tubules are 
attached laterally (not shown) to the hindgut. (Drosophila image courtesy of Nicolas 
Gompel, adapted for use under Creative Commons Attribution NC 3.0 Unported.)  
Quantification of birefringent concretions in DM Malpighian tubules  
Each group of DM were incubated for 10 days total. Flies received 5 days of the 
lithogenic or nutrient containing food, and five days were spent with a daily dose of 
rapamycin with 5% sucrose in ethanol or 5% sucrose in ethanol alone. All groups began 
on non-lithogenic food for consistency. All Malpighian tubules were dissected on day 10, 
where the last 24-hour period was on lithogenic to ensure maximal stone burden. The 
degree of DM calcium oxalate concretions was defined as the total birefringent pixel area 






Life expectancy was analyzed via Kaplan-Meyer Curve, Cox Proportional Hazard 
model and Log-Rank Test on R (Version 1.3.1093 © 2009-2020 RStudio, PBC). 
Malphigian tubule concretion birefringence intensity was measured via ImageJ [ImageJ 
Version 1.51(100)) pixel analysis (Rasband, W.S., ImageJ, U. S. National Institutes of 
Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2018]. When 
appropriate, pixels were adjusted by dividing the total number of pixels by the number of 
specimens represented in the image field. In order to approximate a normal distribution, 
the number of pixels per MT in view for all groups were normalized by taking the square-
root of each measurement. Statistical analysis using SPSS (IBM SPSS Statistics v25) for 
mean normalized pixel/MT for each group was analyzed with an analysis of variance 












DM Survival Analysis 
In total 288 of 300 (96%) male and 299 of 300 (99.6%) female DM had end events 
through 86 days of analysis (Table 3.1). Male DM on oxalate + rapamycin CAFE treatment 
had lower survival compared to female DM on same treatment (23 days vs 49 days,  
Table 3.1; HR 0.57, 95%CI: 0.40 – 0.82, p <0.001 Figure 3.2 and 3.3). Male DM on oxalate 
+ rapamycin CAFE treatment had significantly shorter median survival compared to male 
DM on normal food + rapamycin CAFE treatment (23 vs 35 days, Table 3.1; HR 0.61, 
95% CI: 0.41 – 0.89, p-value = 0.01, Figure 3.1 and 3.3). Male DM on oxalate + rapamycin 
CAFE treatment had significantly shorter median survival compared to male DM on 
oxalate + normal food ad libitum treatment (23 vs 48 days, Table 3.1; HR 0.52, 95% CI: 
0.36 – 0.75, p-value = <0.001, Figure 3.1 and 3.3). Male DM on oxalate + rapamycin 
CAFE treatment had longer median survival compared to the oxalate + vehicle CAFE 
treatment but did not reach threshold for significance (23 days vs 23 days, Table 1; HR 




Male  DM on normal food + rapamycin had significantly longer life expectancy than 
male DM on oxalate + vehicle treatment (35 days vs 23 days, Table 1; HR: 2.34, 95%CI: 
01.60 – 3.43, Figure 3.4). Male DM on normal food + rapamycin CAFE treatment had 
significantly shorter median survival compared to female DM equivalent treatment (35 
days vs 37 days, Table 1; HR 0.38, 95%CI: 0.26 – 0.95, p = 0.026, Figure 3.4). Male DM 
treated with oxalate + vehicle had significantly shorter survival than female DM treated 
with equivalent treatment (31 days vs 23 days, Table 1; HR 0.49, 95%CI 0.34 – 0.71, p < 
0.001, Figure 3.3). No significant difference in median survival was seen between male 
DM on oxalate + rapamycin CAFE treatment compared to male DM on normal food + 
vehicle. Male DM on ad libitum lithogenic diet had no significant difference in survival 
compared to male DM on normal food + rapamycin CAFE treatment (48 days vs 35 days, 
HR 1.17, 95%CI: 0.80 – 1.7, p = 0.42, Figure 3.5). Male DM on ad libitum lithogenic diet 
had longer median survival than male DM on normal food + vehicle CAFE treatment (HR 
2.04, 95%CI 1.42 – 2.90, p < 0.001, Figure 3.5).  
There was no significant difference in median survival between female DM on 
oxalate + rapamycin CAFE treatment compared to other females (Figure 3.1 and 3.6). 
Female DM on oxalate + vehicle treatment had significantly lower survival compared to 
female DM on normal food + vehicle (31 days vs 33 days, Table 1; HR 0.66, 95%CI: 0.46 
– 0.95, p = 0.024, Figure 3.6). Female DM on normal food + rapamycin CAFE treatment 
had longer median survival compared to male DM on the same treatment (37 days vs 35 
days, Table 3.1; HR 1.5, 95%CI: 1.04 – 2.20, p = 0.029, Figure 3.6). There was no 
significant difference in median survival seen between male and female DM on ad libitum 















Table 3.1 Kaplan-Meier survival data for Male and Female DM survival analysis.  
N = sample size, Event = death, Ox Rap = 0.1% sodium oxalate + rapamycin, Ox  V = 
0.1% sodium oxalate + vehicle (no rapamycin). NF Rap = normal food + rapamycin. NF 



























Figure 3.1 Kaplan-Meier survival curves for male (top) and female (bottom)  
D. melanogaster given lithogenic or non-lithogenic diets, with or without rapamycin.  
Vehicle denotes D. melanogaster cohorts that were fed non-nutritious solution without 
rapamycin by CAFE. Reference cohort for comparison is 0.1% sodium oxalate + 
rapamycin group for both males and females. Significance by Log-Rank test, levels: * = 





Figure 3.2 Kaplan-Meier survival curves comparing ad libitum lithogenic diet treatment to 
CAFE lithogenic treatment + rapamycin in female and male D. melanogaster.  
Female 0.1% sodium oxalate + rapamycin group is reference curve for significance 






Figure 3.3 Forest plots of Hazard Ratios for male DM on lithogenic + rapamycin (top) or 






Figure 3.4 Forest plots of Hazard Ratios for male DM on normal food + rapamycin (top) 





Figure 3.5 Forest plot of Cox Proportional Hazard Ratios for male DM on ad libitum 









Figure 3. 6 Forest plots of Hazard Ratios for female DM on lithogenic + rapamycin (top) 





Figure 3.7 Forest plots of Hazard Ratios for female DM on normal food with rapamycin 





Figure 3.8 Forest plots of Cox Proportional Hazard Ratios for female DM on ad libitum 








Ex vivo imaging of Malpighian tubules and effect of rapamycin on concretion 
birefringence. 
Female DM who were available for full MT analysis ranged between 21 and 43 
individual DM per treatment group (Table 3.2). The total of dissected MT for analysis 
ranged from 67 to 104 per group in female DM and the median number Malpighian tubules 
isolated intact is displayed in Table 3.5. 
 
Table 3.2 Descriptive statistics of female DM Malpighian tubules dissections for each diet. 
Birefringence measured by square root transformed pixels per Malpighian tubule. 
0.1%/NF = 0.1% sodium oxalate – normal food protocol. NF/+Rapa = normal food – 
rapamycin protocol. NF/-Rapa = normal food without rapamycin. 0.1%/+Rapa = 0.1% 








Male DM in each group who were viable for full MT analysis ranged between 18 
and 39 individual DM per group (Table 3.3), and had a total number of dissected MT of 
45 to 122 per group for analysis. The median number of intact MT isolated per fly are 
demonstrated in table 3.6. 
 
Table 3.3 Descriptive statistics of male DM Malpighian tubules dissections for each diet. 
0.1%/NF = 0.1% sodium oxalate – normal food protocol. NF/+Rapa = normal food – 
rapamycin protocol. NF/-Rapa = normal food without rapamycin. 0.1%/+Rapa = 0.1% 





DM that did not get exposure to oxalate displayed very little birefringence 
compared to groups treated with oxalate-based diets (Figure 3.9 D-E, I-J). Sex did not 
affect Malpighian tubule birefringence when DM were fed equivalent diets (Figure 3.9). 
There was no difference in MT birefringence in DM fed normal food without oxalate, 
regardless of rapamycin treatment status.  Furthermore, there was no difference in 
birefringence of DM on oxalate alternated with 24h of normal food (0.1%/NF) or vehicle 
without rapamycin (0.1%/-Rapa). 
 
Figure 3.9 Representative images of Malpighian tubules. 
(A-E) Bright-field and (F-J) plane-polarized light microscopy at x 40 magnification for 
dissected male and female DM Malphigian tubules at eleven days post-eclosure. 
NF/0.1% = 0.1% sodium oxalate – normal food protocol. 0.1% = 0.1% sodium oxalate 
protocol. NF = normal food protocol.  Rapamycin treatment indicated by “+ Rap” (C, E, H, 





The oxalate/rapamycin dietary protocol resulted in significantly less mean MT 
birefringence per Malpighian tubule compared to DM on both oxalate/normal food (16 vs 
33, p < 0.01, Figure 3.10) and oxalate/vehicle protocols (16 vs 30, p < 0.01, Figure 3.10). 
DM fed oxalate/rapamycin had significantly higher MT birefringence compared to DM fed 
normal food with rapamycin (16 vs 3, p < 0.01, Figure 3.10) and normal food without 
rapamycin (16 vs 4, p<0.01, Figure 3.10). Drosophila fed 0.1% oxalate/normal food had 
significantly more MT birefringence compared to both normal food/vehicle (30 vs 3, p 
<0.01, Figure 3.10) and normal food/rapamycin (30 vs 4, p<0.01, Figure 3.10) groups.  
Male DM fed 0.1% oxalate/rapamycin had significantly lower MT birefringence 
compared to 0.1% oxalate/normal food (19 vs 28, p < 0.01, Figure 3.10) and compared 
to 0.1% oxalate/vehicle (16 vs 28, p <0.01, Figure 3.10). The oxalate/rapamycin protocol 
had significantly greater mean normalized MT birefringence compared to DM fed normal 
food protocols with rapamycin (16 vs 2, p<0.01, Figure 3.10) and without rapamycin (19 




Figure 3.10 Box plot of DM normalized Malpighian tubule birefringence under  
plane-polarized light microscopy.  
Female = white and male = grey. 0.1%/NF = 0.1% sodium oxalate/normal food protocol. 
NF/+Rapa = normal food/rapamycin protocol. NF/-Rapa = normal food without rapamycin. 
0.1%/+Rapa = 0.1% sodium oxalate – rapamycin protocol. 0.1%/- Rapa = 0.1% sodium 









Measuring life expectancy is simpler than measuring overall decline in function of 
DM with advancing age and can be used as a crude surrogate for stress.148 The degree 
of DM calcium deposition in the Malpighian tubule (MT) is associated with both oxalate 
load and reduced life expectancy. Other studies have shown that MT concretions are 
inversely correlated with life expectancy.138  As expected, calorie restricted lithogenic 
diets are associated with significantly lower median survival compared to calorie restricted 
non-lithogenic treatments in male DM. Intermittent dosing of rapamycin via CAFE extends 
relative median survival of male DM fed a lithogenic diet compared to vehicle. Since 
mTOR inhibition by rapamycin is known to induce autophagy86, we hypothesized that this 
treatment would help reverse calcium oxalate crystal damage by improving the ability of 
DM to clear ROS and damaged proteins.  
We hypothesized that increased clearance of dysfunctional proteins and lower 
ROS following rapamycin treatment would lead to an increase in life expectancy and 
tolerance of calcium oxalate crystals. However, compared to available literature our 
treatment did not improve life expectancy.138 However, our finding that rapamycin extends 
the relative median life expectancy of wild type DM compared to vehicle is consistent with 
other studies. For example, Wang et al. described a median survival advantage of a 
mitochondrial dysfunction mutant of Drosophila treated with 100 µM of rapamycin daily 




Oxalate does also appear to be toxic to DM, resulting in lower relative life 
expectancy. In these cases, rapamycin may improve survival independent of sodium 
oxalate treatment. For context, the average life expectancy of DM ranges between 60 – 
90 days and our DM given rapamycin on a lithogenic diet have a median survival of 33 
days. Ali et al. reported very few DM fatalities before 20 days with median survival of 
about 35 days for DM on an ad libitum lithogenic diet with 0.1% sodium oxalate.138,150 The 
male DM given a lithogenic diet in our study have median survival of 33 and 27 days in 
the rapamycin and vehicle groups respectively. In fact, the median ages of our DM in all 
groups are shorter than in the literature.149–151 Our DM also appear to perish earlier in 
their life cycle, with nearly 60% of deaths before 20 days of age.  
We noted shorter overall life span and increased premature death in our DM 
across all treatment groups compared to the available literature.138,150 Reduced life 
expectancy may be related to the daily exposure to anaesthesia in order to change to 
agar for the purpose of administering rapamycin via CAFE. Specifically, recurrent CO2 
narcosis may have made our flies more susceptible to other causes of death such as 
infection. Hypercarbia has been shown to decrease host resistance to bacterial infection 
in Drosophila via upregulation of metabolic genes and reduced innate immune response 
to infection.152 Unregulated host metabolism and poor resistance to infection may produce 
ROS and impair the epithelial lining integrity of the Drosophila gut, in addition to altering 




Fan et al. have shown that rapamycin can rescue intestinal epithelial integrity and 
improve life expectancy in a DM model of aging.153 Rapamycin and mTOR inhibition can 
limit the harmful effect of reactive oxygen species by influencing the proliferation rate of 
intestinal stem cells and immune cells,.153 Therefore, improvement in intestinal integrity 
is a mechanism by which rapamycin may have improved relative median survival between 
in DM fed a lithogenic diet. A competing hypothesis is that rapamycin acted on its 
microenvironment to improve median survival. Rapamycin has known antifungal 
properties that help ward off fungal organisms with pathologic potential in DM like C. 
neoformans.100,154 Importantly, no macroscopic evidence of fungal infection was observed 




Unexpectedly, male DM fed ad libitum calorie diet with alternating lithogenic days 
had the longest median life expectancy. In other studies, lithogenic diet treatment has a 
dose-dependent effect on reducing median life expectancy.138 Additionally, environments 
of low nutrient availability should reduce mTOR activity, removing a barrier for autophagy 
to occur.94 In particular, the rapamycin groups undergoing brief periods of dietary 
restriction were expected to have longer life expectancy as seen by others who have 
studied life span extension by by dietary restriction with and without rapamycin.82,155 In 
the literature, rapamycin and dietary restriction are not equivalent, as they appear to act 
in some cases synergistically to improve life expectancy.145,156 However, the CAFE 
method of drug delivery in DM is known to have lower survival compared to equivalent 
strains fed ad libitum.157 Additionally, our dietary restriction treatment may have allowed 
for differential bacterial survival and create a hostile microenvironment. For example 
alphaproteobacteria has been suggested as a bacterial taxon associated with longevity 
in aging flies.158 It is known to be impacted by rapamycin treatment, which has 
subsequently been linked to a mechanism for reduced mortality and health decline in 




DM fed ad libitum alternating every other day with a lithogenic diet may have had 
a the longest median survival in part due to the constant presence of propionic acid in its 
environment. Propionic acid is a short-chain fatty acid (SCFA) that acts as a potent anti-
fungal agent by inducing mercaptase-dependent apoptosis in eukaryotes.159,160 
Furthermore, Propionibacterium and Lactobacilli are known to produce propionic acid as 
a preservative by anaerobic fermentation of carbohydrates.161 Propionic acid derived from 
food is also required for proper phospholipid membrane homeostasis in DM.162 Without 
propionic acid supplementation, it is possible Lactobacilli and Propionibacterium are 
outcompeted by other endogenous non-propionic acid producing microorganisms leading 
to inefficient lipid metabolism and disordered epithelial defences. Other researchers have 
suggested that changes in endogenous microflora leading to dysbiosis  may have a 
deleterious effect on DM lifespan via impaired immune or stem cell function, epithelial 
barrier function or through direct infection by microorganisms.163–165  
Intermittent treatment with rapamycin did not increase median survival for female 
DM fed any diet. Furthermore, treatment-for-treatment, median life expectancy was 
greater for female DM compared to male DM. It is a known phenomenon that male DM 
are more sensitive to starvation and stress due to a greater tendency to move and 
compete for limited resources compared to females, leading to quicker wasting of stored 




Additionally, it is know that male and female DM harbour different microbiota in 
their environment.164 Therefore, they may have responded differently to our treatments 
due to differences in microorganisms in their environment that was not controlled between 
genders. This could be mitigated in the future by using gnotobiotic (a “known 
microbiome”) or axenic (“germ free”) DM. Interestingly, the DM endogenous parasite 
Wolbachia spp. is associated with increased larval male-specific death and an increase 
in female median survival likely due to impaired oogenesis, reproductive function steroid 
hormone metabolism and energy conservation.167,168  Furthermore, mTORC1 signalling 
has been shown to suppress Wolbachia titres in oocytes, leading to reduced ecdysone 
(steroid hormone) signalling that has been shown to significantly increase life expectancy 
in DM.169 Since meiosis and reproduction is a non-life extending, energy-consuming 
processes, inhibiting this process may allow female DM to tolerate stressful situations 
better than male DM in our study.168  
Another competing explanation is differential compensatory “binge eating” when 
placed back in an ad libitum diet condition. This is in agreement with work by Farhadian 
et al. that showed both male and female DM transiently increase their rate of food intake 
following fasting.170 In fact, the female compensatory increase in rate of food intake lasted 
for approximately 24-hours in their study; whereas, males returned to baseline feeding in 
12-hours, a finding that has been reproduced by others.170,171 In our study, since females 
lived longer it may be because of a higher overall intake of nutritious or antimicrobial 
compounds following a period of fasting, helping them prevent confounding causes of 




Finally, it is possible that a fasting environment during treatment with either 
rapamycin or vehicle of 24-hours duration is not adequate to achieve benefits of mTOR 
inhibition. Furthermore, short intermittent fasting may be beneficial or harmful at different 
points in the DM life cycle.155 Additionally, other authors have studied fasting durations 
ranging from 24-hours to 7 days in duration.155,171,172 It is reasonable to assume therefore 
that our fasted DM may not have received the full physiologic benefits of reduced mTOR 
activity. Therefore, fasted DM would be at a survival disadvantage given less nutrients to 






Ex vivo crystal analysis 
Drosophila melanogaster exposed to 0.1% sodium oxalate in their diet form highly 
birefringent calcium oxalate monohydrate crystals in their Malpighian tubules.138 In 
agreement with our hypothesis, rapamycin treatment resulted in fewer visible MT calcium 
oxalate concretions compared to DM on other lithogenic diets. This result suggests that 
intermittent rapamycin may reduce nephrolithiasis in our dietary Drosophila model of 
calcium oxalate nephrolithiasis.  
Our findings are primarily hypothesis generating for future study of the role of 
mTOR in nephrolithiasis. First, calcium and oxalate are small substrates that can travel 
across epithelial cell boundaries into the body through a paracellular mechanism.173,34 
Calcium oxalate crystallization is dependent on the concentration of oxalate and calcium 
in solution; therefore, gut homeostasis and effective oxalate uptake is an interesting target 
for the prevention of nephrolithiasis.  Worsening epithelial barrier function often leads to 
increased paracellular transport of solutes.174 Indeed, impaired epithelial barrier function 
in humans is seen following antibiotic treatment, fiber-poor diets high in processed foods, 
patients with metabolic syndrome and obesity, and aging.175 Therefore, direct toxic insult 
on epithelia and/or alterations of the gut microbiome may lead to a higher systemic 
oxalate load and filtration into the Malpighian tubule lumen through increased oxalate 
absorption from the gut.176 Fan et al. have demonstrated that rapamycin can rescue 
epithelial stem cell function in older Drosophila with impaired gut barrier function and 
homeostasis.153 Further study is required to confirm whether modulation of mTOR in DM 
may impact oxalate uptake from a dietary source or whether it acts at the level of the 




An advantage of the DM model organism includes the possibility for future 
organotypic studies via the UAS-GAL4 system.133 By employing a renal-specific (uro) and 
UAS-GAL4 system targeting one of the interacting proteins in the mTOR pathway or 
mTOR itself, one could elucidate whether mTOR activity is important at the level of 
oxalate transport in the gut or via its action at the Malpighian tubule (Figure 4).    
 
Figure 4 UAS-GAL 4 system with proposed Malpighian tubule tissue promoter uro genes 
producing null mTOR mutant. This technique requires isolation of pure male DM with the 
uro-GAL4 construct gene and pure female containing UAS-dTOR2L1. Upon activation of 
uro by endogenous inducing transcription factors (TF), GAL4 is produced. The protein 
product of Gal4 then interacts with the UAS region of the gene construct carrying the 
mTOR mutant. This interaction leads to increased transcription of the desired gene 




Second, rapamycin may upregulate autophagy leading to reduced calcium oxalate 
MT concretion area. Though we did not quantify autophagy in our study, our results 
support previous experiments by Unno et al. who showed improved efficiency of 
autophagic flux in renal tubular cells exposed to calcium oxalate when treated with 
rapamycin.9 Overall this led to decreased luminal calcium oxalate stone formation and 
improved clearance of calcium oxalate crystals. There was a significant difference in 
Malpighian tubule concretions in DM fed non – lithogenic ad libitum and all DM fed 0.1% 
oxalate without rapamycin treatment. Therefore, rapamycin reduced the amount of 
calcium oxalate concretions in Malpighian tubules, but it may not inhibit the crystallization 
process completely. In other words, calcium oxalate nephrolithiasis still occurs; however, 
the further aggregation and growth of calcium oxalate crystals may be hindered by 




In some settings, autophagy may actually exacerbate stone formation. In contrast 
to apoptosis which is a process of controlled cell death, autophagy is the process by which 
cells recycle macromolecules.93 Duan et al. showed that chloroquine inhibition of 
autophagy reduced tubular inflammation and calcium oxalate deposition.179 Indeed, their 
study found that calcium oxalate crystals led to more immature apoptotic vesicle formation 
at very high concentrations of oxalate (0.75 mM for 48h), a finding that was not seen in 
the study by Unno et al. who used a nephrocalcinosis model of calcium oxalate formation 
exacerbated by glycolate administration.9,179 The latter study may be more relevant for 
the physiology of idiopathic calcium oxalate kidney stones in man. The study by Duan et 
al used chloroquine in order to inhibit autophagy. Although chloroquine administration 
does lead to inhibition of autophagy it also directly impairs cytoskeletal rearrangement 
required for the management endoplasmic reticulum stress.180 The endoplasmic 
reticulum is important for processing secreted proteins like Tamm-Horsfall protein, thus 
potentially explaining why this mechanism of apoptosis inhibition may confound the study 
of nephrolithiasis inhibtiors.63,180,181 However more research needs to be done on timing 
of autophagic activation/inhibition in relation to serum oxalate load and mTOR inhibition. 
Further support for rapamycin being positively associated with nephrolithiasis protection 
includes work describing a reduction in tubulointerstitial inflammation and fibrosis in 




 Importantly, there was some variability in the degree of stone burden within 
individual DM of the rapamycin group fed a lithogenic diet. Furthermore, in both the 
rapamycin and vehicle lithogenic diet groups, there is a 24-hour period where flies are 
essentially calorically restricted to just a small amount of sucrose and either capillary 
containing vehicle or rapamycin solution. There does not appear to be significantly lower 
calcium oxalate MT concretions in calorically restricted compared to ad libitum caloric 
intake on a lithogenic diet. This finding casts doubt on our hypothesis that fasting between 
0.1% sodium oxalate loads reduces Malpighian tubule concretions through inhibition of 
the mTOR pathway. However, it is possible that the duration of fasting in our study was 
not adequate to inhibit mTOR similar to rapamycin treatment. As a result, we did not note 
significant differences between our ad libitum diet conditions and those experiencing a 
period of fasting on agar. It is known that the metabolic effects of dietary restriction, of 
which fasting is a common strategy, is a complex endocrinologic process. Indeed, others 
have found that the physiologic benefits of fasting may be enhanced by rapamycin and 




Additionally, timing of dietary restriction in the life of DM may be important. 
According to the pleiotropic hypothesis regarding the benefits surrounding autophagy and 
mTOR inhibition, actions that are detrimental earlier in life may be beneficial later (and 
vise versa).94  Interestingly, Catterson et al. found that if DM were fed only twice a week 
until age 30 days, they had significantly longer life expectancy compared to DM who were 
either always fasting on a 2:5 schedule until death or always ate ad libitum.155 DM that 
fasted throughout life actually had the shortest life expectancy in the aforementioned 
study.155 The fact that fasting is not a universally protective activity suggests a possible 
epigenetic mechanism for its benefits.183 Given the correlation between non-metabolic 
syndrome phenotype, aging, and relative protection from nephrolithiasis, further study on 
this topic is needed to determine whether the benefits of different periods of fasting has 
any true impact on nephrolithiasis pathogenesis.  
Another hypothesis may be that rapamycin promotes the production of effective 
natural stone-inhibitors. Theoretically, mTOR inhibition should improve autophagy and 
rapidly clear dysfunctional or misfolded proteins in cells affected by inflammation.95 The 
net result would be properly folded stone-inhibiting proteins secreted into urine. However, 
this is a less likely hypothesis as primary cilia are absent in Drosophila renal tubules.177 
Since primary cilia increases surface area for exchange of solutes, this suggests that 
there may be lower bulk secretory and resorptive processes at the level of the Malpighian 
tubule in DM compared to mammals.177 Indeed, in our literature search we could not 
identify any articles suggesting a beneficial effect of rapamycin or mTOR inhibition on the 
production of molecules like osteopontin, Tamm Horsfall protein or other endogenous 




Taken together, our findings suggest that calcium oxalate deposition in DM 
Malpighian tubules does not require daily exposure to sodium oxalate and that the amount 
concretion is reduced by rapamycin. Although fasting did not appear to influence overall 
survival or Malpighian tubule calcium oxalate concretions, our data is inconclusive to 
claim an effect on nephrolithiasis and further study is needed to clarify this. Treatment 
with rapamycin appeared to help mitigate the adverse effect of sodium oxalate on both 
median survival and Malpighian tubule concretions, and the mechanisms underlying this 
are likely multifactorial. In addition, the gut microbiome and the effect of different genders 
may have also impacted our results and should be accounted for in future studies. 
Furthermore, rapamycin treatment may reduce mTOR activity exacerbated by calcium 
oxalate crystals adherence to renal tubule-like epithelial cells. Reduced mTOR may 






Limitations and assumptions of study 
Although we could have censored individuals that clearly died on transfer or by 
trauma, it is not possible to know the cause of death of all DM subjects for certain and we 
analyzed our life expectancy data in a non-informed manner to avoid bias. Furthermore, 
we cannot definitively state whether or not confounding factors which affect life 
expectancy influenced the weak correlation between stone formation and life expectancy 
in our model. We do assume by equal treatment of all groups that confounding variables 
should be minimized. We also cannot guarantee equal drug or nutrient uptake amongst 
our Drosophila subjects. Since it is a closed environment with limited resources, some 
individual DM may outcompete others for resources like sucrose in our CAFE system. 
Therefore, some may be overdosed while others may be underdosed. This may explain 




Observation of large cohorts of age-matched Canton S Drosophila melanogaster 
allows for population level information about the progression of aging and how treatments 
impact this process.184 Arking et al found that longer Drosophila life span was related to 
increased resistance to oxidative stress and by reducing the impact of oxidative damage 
due to increased gene expression of antioxidant genes she could extend life 
expectancy.185  In contrast to diets leading to metabolic syndrome, rapamycin and dietary 
restriction have been shown to improve life expectancy in yeast, flies as well as mice in 
part by limiting ROS.86,149 Though life span extension is associated with slower 
senescence, shorter life spans are not necessarily associated with a “premature aging” 
phenotype.186,187 In addition, body size and therefore mTOR activity may also vary in 
CantonS DM themselves. Others have shown that variation in body size alone can explain 
40% of variation in life expectancy.188 This variance may have produce a significant 
amount of noise in the interpretation of life expectancy data in relation to unequal baseline 
mTOR activity.188 We did not see extended life expectancy, therefore, the relative 
improvement in survival seen in our study may be confounded by DM succumbing to 




We chose pharmacologic inhibition of mTOR over a genetic model in Drosophila 
for several reasons. Rapamycin is more readily available in reagent stock than available 
mutants of mTOR in Drosophila that are not fatal before adulthood when the Malpighian 
tubules are available for dissection. De novo screening for mTOR mutants would be 
required in order to achieve this and this was not reasonably possible within the time 
frame of this project. However, there are significant disadvantages when using 
pharmacologic inhibition of mTOR with rapamycin. Due to the low water solubility, short 
half-life in acidic environment such as DM food, uncertain compatibility in solution with 
sodium oxalate and temperature instability of rapamycin in solution; rapamycin in our 
model had to be delivered via CAFE capillary aliquots from a stock solution.189 An 
inevitable complication of the CAFE method is unequal dosing between flies of the same 
vial and survival stress. However, we would expect this to be randomly distributed in each 
vial and not dependent on treatment group. Notably, the group with the greatest survival 
was treated ad libitum without CAFE. Therefore, caloric restriction in the setting of a 






In contrast to rodent models, Drosophila have an open circulatory system, and as 
a result endothelial/vascular cell dysfunction is not easily modelled.133 Since Randall’s 
plaques are thought to be of vascular origin, we cannot interrogate this area of 
nephrolithiasis in DM.36,56,138,147 Given that mTOR activity is required for wound healing 
and epithelial-to-mesenchymal cell transformation, this is an important short-coming of 
the dietary DM model of nephrolithiasis and mTOR action. Furthermore the immune 
system of Drosophila also differs greatly from humans.190 While others have shown the 
activation of autophagy by mTOR inhibition may reduce Randall’s plaques, DM do not 
form Randall’s plaques. Therefore, rapamycin may also act in other ways to prevent 
nephrolithiasis.9  
Though Drosophila is an excellent genetic model organism, “strong” direct mutants 
of mTOR lead to arrest in embryological development and may not survive long into 
adulthood.191 In addition, rapamycin also indirectly affects mTORC2 activity, which can 
lead to a diabetic phenotype in face of increased sugar loads via relative β cell hypoplasia 
of the pancreas depending on chronicity of use and expression of FKB-506 binding 
proteins.192,193 Therefore, for control of when and for how long we could initiate mTOR 
inhibition we decided to use a pharmacologic intervention in addition to our sodium 
oxalate dietary strategy. Considering another alternative would be to repeat this study 
protocol with a complete competitive antagonist of mTORC1 such as Torin1 or a water 




However, rapamycin is only a partial allosteric antagonist of mTORC1 at treatment 
doses.101 The pharmacokinetic profile of rapamycin in DM is unknown, but the likely 
distribution and therefore half-life is difficult to ascertain limiting efforts to optimize a 
dosing schedule. For one, they have an erythrocyte analogue (hemocyte), it represents 
less than 10% of its total hemolymph cells.195 In total, 95% of rapamycin is bound to 
immunophilins in human erythrocytes. DM do have an analogue to cytochrome P450 3A4, 
and therefore may have similar enzymatic processing of rapamycin into up to 16 different 
metabolites.196 DM do not have an important role for estrogens, and females are generally 
larger than males; therefore, from gender is expected to play a lesser role in the tissue 
distribution and metabolism of rapamycin compared to humans.107,114,197  
The DM model itself for the study of nephrolithiasis is not without its limitations. 
Due to the lack of a vascular system and lymphoid structures, the biochemical and 
inflammatory environment in DM are not analogous to humans. Furthermore, DM 
normally feeds on high-sugar nutrients and has evolved adaptations necessary to prevent 
hyperglycemia, such as storage of glucose as hemolymph trehalose.131 In addition, 
utilizing a dietary model of DM stone disease requires a large sample size of flies in order 
to reduce the variation in feeding habits of individual flies. Though DM are easy to house, 




Drosophila are also too small to ensure that each individual receives the same 
amount of any dietary or drug intervention. The CApillary FEeding (CAFE) assay is a 
common, well established method to circumvent the difficult problem of dosing 
medications that may have low half-lives at specific temperatures or pH levels (Figure 
2.1).143 Finally, DM hatch from a larval phase whereby they are constantly are feeding 
and ambulatory, followed by a period of 3-4 days of fasting while awaiting to pupate into 
their final fly form.198 Consequently, when studying mTOR which may be sensitive to 
states of fasting, the results may not be applicable to humans as we do not typically have 
these types of dietary patterns. 
We are unable to claim that our rapamycin treatment reduced calcium oxalate 
concretions due to direct mTOR inhibition. We also must assume that rapamycin did not 
affect the feeding behaviour of DM to feed on the capillary solution. It has been shown 
that DM do not consume all drugs administered by CAFE at the same rate.143  We also 
assumed that the reason for improvements in life expectancy, as well as calcium oxalate 
concretions, was due to direct DM mTOR inhibition rather than an effect on microbial 





Ultimately, other studies are required to elucidate whether it is a drug phenomenon 
of rapamycin on the environment, or, mTOR inhibition in DM that exacerbates 
nephrolithiasis. For example, should a null-mutant mTOR Drosophila strain such as 
dTOR2L1/dTORl(2)k17004 that is phenotypically smaller than CantonS show similar results 
to our study it would strengthen the hypothesis that mTOR inhibition directly acts on DM 
cells to influence nephrolithiasis rather than the environment. Additionally, if we repeated 
our study in germ free DM it may refute the idea that rapamycin worked by modulating 
the microbiological environment of our subjects leading to relative protection from 
nephrolithiasis. In our fasting conditions, we may be missing the optimal duration or time 
for fasting to prevent nephrolithiasis, limiting our ability to assess its impact. Furthermore, 
without a measurement of apoptosis or protein synthesis, we cannot conclude which 











Conclusions and future directions 
In conclusion, we are the first to demonstrate that intermittent rapamycin 
administration by CAFE is effective at reducing calcium oxalate Malpighian tubule burden 
in a dietary model of DM fed a 0.1% sodium oxalate diet every other day. In terms of 
mTOR inhibition and its role in nephrolithiasis, our study supports the recent findings of 
Unno et al. who suggested that rapamycin and mTOR inhibition reduce calcium oxalate 
crystal growth in mice.9 Our study is novel as it suggests that intermittent dosing of 
rapamycin may be adequate to inhibit calcium oxalate nephrolithiasis. Furthermore, this 
work can be used as a pilot for further studies in Drosophila examining the mTOR pathway 
in calcium nephrolithiasis. Though longer life expectancy did not occur with rapamycin 
treatment, this may be confounded by limitations innate to using CAFE for drug delivery 
including the lack of propionic acid supplementation, feeding rate controls, and the 
possibility of microorganism involvement with a different gender predominance which may 
have impacted our findings. In order to study whether fasting can resilience mitigate 
calcium oxalate concretion formation, we can design relatively affordable optimization 
studies to look at the optimal microenvironment, duration of fasting and/or oxalate loading 




In order to confirm our statement that rapamycin affects calcium oxalate stone 
formation, either at the level of the gut or Malpighian tubule epithelia, we would need to 
measure the output of DM mTOR activity via p-S6K or p-eIFB4 to ensure DM had 
physiologically relevant mTOR inhibition. However, systemic administration of rapamycin 
would not allow us to elucidate if nephrolithiasis is protected by mTOR inhibition at the 
level of the Malpighian tubular epithelia or gut in DM.  To solve this, we would also need 
to create tissue-specific mutants in order to achieve knowledge of the tissue most 
important for prevention of nephrolithiasis in our model.  
To accomplish the goal of identifying where mTOR is most needed in the 
prevention of nephrolithiasis, DM can be used generate tissue-specific mutants via the 
UAS-GAL4 system.177 In this genetic method, a tissue-specific promotor region of DNA is 
combined with the GAL4 gene, a transcription factor.199 Once GAL4 is produced in the 
tissue of interest, it can bind the UAS promoter and drive the expression of any gene of 
interest. For example, we could generate UAS-GAL4 flies with a uro promoter region, and 
drive the expression of a weak functionally null-mutant of mTOR like dTOR2L1 only in the 
Malpighian tubule (Figure 4).  This is possible because of the specificity of uro for 
Malpighian tubule structures. If this model were to show reduced calcium oxalate burden, 
it would strengthen the hypothesis that mTOR activity is important at the level of the 
Malpighian tubule rather than elsewhere. We could also examine the effect of 
pharmacologic inhibition of mTOR on a knockout model of autophagy to determine the 




Finally, to date mTOR inhibition has only been interrogated for calcium-based 
urolithiasis. Since metabolic syndrome is associated with uric acid stones as well as 
calcium oxalate stones, it would be interesting to determine the impact of rapamycin 
treatment or genetic mTOR inhibition in non-calcium oxalate stones that are also 
associated with aging and metabolic excess. This could be accomplished with a DM uric 
acid model of urolithiasis, which our group has previously developed.134 
Overall, we conclude that inhibition of mTOR activity shows promise in reduction 
of calcium oxalate stone prevention in a dietary Drosophila melanogaster model of 
nephrolithiasis. In particular, we are the first to show that calcium oxalate concretions can 
be created with intermittent sodium oxalate treatment. Furthermore, we show that these 
concretions can be significantly reduced in Drosophila melanogaster by intermittent 
rapamycin treatment delivered via a capillary feeding system. This is important evidence 
as it supports the creation of genetic DM models to further investigate which metabolically 
active pathways downstream from the mTOR pathway are most strongly associated with 
prevention of calcium oxalate concretions. Once the downstream mTOR pathways with 
the most potential impact on calcium oxalate crystal formation are identified, these may 
then be targeted for further study in mammalian models.  Ultimately, this pilot project  will 
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